Vascular News and Research

RSS

Scientia Advisors: Unmet need for new medical technologies to treat CVI and blood clots

In light of an aging population and increasing chronic vascular disease, there is a tremendous unmet need for new medical technologies to treat potentially dangerous chronic venous insufficiency (CVI) and blood clots, according to a Scientia Advisors review of the vascular device market released today. Both the CVI and the thrombosis segments present significant opportunities for medical device innovators.

3 Feb 2011

Isis commences ISIS-FXIRx Phase 1 study for treatment of clotting disorders

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of ISIS-FXIRx, an antisense drug designed to treat clotting disorders. ISIS-FXIRx inhibits the production of Factor XI, a clotting factor that is an important component of the coagulation pathway. Because of its role in the intrinsic coagulation pathway, inhibition of Factor XI could offer an effective approach for preventing the formation of blood clots with a lower risk of bleeding.

2 Feb 2011

FDA approves FSS's FlexStent system IDE for OPEN Trial

Flexible Stenting Solutions, a leading developer of next generation peripheral arterial, venous, neurovascular and biliary stents, announced today that it has received full FDA Investigational Device Exemption approval for its FlexStent Femoropopliteal Self Expanding Stent System.

2 Feb 2011

Cutera launches Excel V laser system for Dermatologists and Plastic Surgeons

Cutera, a leading worldwide provider of laser and other energy-based aesthetic systems for practitioners worldwide, today announced the launch of its Excel V laser system ─ a unique vascular work station designed specifically for the core-market of Dermatologists and Plastic Surgeons.

2 Feb 2011

Study suggests human amniotic cells 'cross talk' with melatonin receptor MT1

Human amniotic epithelial cells, stem cells derived from human placenta left over from live births and generally discarded, proliferated and differentiated when they interacted with one kind of melatonin receptor, MT1. This potentially therapeutic response occurred when the stem cells were transplanted into laboratory test tube and animal models of stroke. The same cells did not perform similarly when interacting with melatonin receptor MT2.

2 Feb 2011

First blood-based diagnostic test for LAM

Circadian Technologies has announced today that in conjunction with Cincinnati Children's Hospital Medical Center it has begun offering its LAM diagnostic, which is offered as a laboratory test compliant with CAP (College of American Pathologists) /CLIA regulations.

2 Feb 2011

Mother’s stroke history can help predict daughter’s risk of heart attack

If you're a woman and your mother had a stroke, you may have a risk of heart attack in addition to a higher risk of stroke, according to new research on family history and heart disease published in the American Heart Association journal Circulation: Cardiovascular Genetics.

2 Feb 2011

Study finds treatment-related mortality with bevacizumab in cancer patients

Cancer patients treated with the chemotherapy agent bevacizumab may be at an increased risk of treatment-related death when the drug is used in combination with other therapies.

2 Feb 2011

Kensey Nash second quarter revenue decreases to $17.4 million

Kensey Nash Corporation, a medical device company primarily focused on regenerative medicine for a wide range of medical procedures, today reported the results for its second quarter ended December 31, 2010.

1 Feb 2011

Covidien first-quarter net sales increase 5% to $2.77 billion

Covidien plc today reported results for the first quarter of fiscal 2011 (October-December 2010). First-quarter net sales of $2.77 billion increased 5% from the $2.64 billion reported a year ago. Foreign exchange rate movement had no impact on the quarterly sales growth rate.

1 Feb 2011

Researchers grow arteries with elasticity of natural blood vessels outside the body

University of Pittsburgh researchers have grown arteries that exhibit the elasticity of natural blood vessels at the highest levels reported, a development that could overcome a major barrier to creating living-tissue replacements for damaged arteries, the team reports in the Proceedings of the National Academy of Sciences.

1 Feb 2011

Red wine polyphenols prevent ageing-induced endothelial dysfunction

The endothelium is the inner lining of our blood vessels and normal functions of endothelial cells include enabling coagulation, platelet adhesion and immune function. Endothelial dysfunction is associated with reduced anticoagulant properties and the inability of arteries and arterioles to dilate fully.

1 Feb 2011

Widespread screening or ultrasound for blocked neck arteries not necessary to determine stroke risk

Widespread screening or routine ultrasound for blocked neck arteries to determine stroke risk isn't necessary, according to new guidelines from the American Heart Association/American Stroke Association, American College of Cardiology and other groups.

1 Feb 2011

Favorable clinical results from Endologix's Nellix technology against EVAR

Endologix, developer of minimally invasive treatments for aortic disorders, announced today the publication of favorable clinical results for the Nellix technology for the endovascular repair of abdominal aortic aneurysm.

1 Feb 2011

Abbott receives US regulatory clearance and Japanese approval for TREK Coronary Dilatation Catheters

Abbott today announced it has received regulatory clearance in the United States and approval in Japan for its TREK and MINI-TREK Coronary Dilatation Catheters for the treatment of coronary artery disease. The TREK system is used in angioplasty procedures and is designed to enable interventional cardiologists to open patients' narrowed coronary arteries. The TREK system received CE Mark and was launched in Europe in May 2010.

1 Feb 2011

FDA approves Boston Scientific's Renegade HI-FLO Fathom Pre-Loaded System

Boston Scientific Corporation today announced that the U.S. Food and Drug Administration has approved its Renegade HI-FLO Fathom Pre-Loaded System for selective access and delivery of diagnostic, embolic and therapeutic materials into the peripheral vasculature.

1 Feb 2011

FDA approves ultrasmall silica inorganic nanoparticle INDA for targeted molecular imaging of cancer

Researchers at Memorial Sloan-Kettering Cancer Center's Nanotechnology Center, along with collaborators at Cornell University and Hybrid Silica Technologies, have received approval for their first Investigational New Drug Application from the US Food and Drug Administration for an ultrasmall silica inorganic nanoparticle platform for targeted molecular imaging of cancer, which may be useful for cancer treatment in the future.

31 Jan 2011

VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the initiation of two studies to further evaluate the efficacy and safety of VB-111 in advanced cancers.

31 Jan 2011

Disparities in limb salvage procedures may be driven by SES, access to high-volume hospitals

Researchers from Brigham and Women's Hospital at Harvard Medical School in Boston, MA have published a study in the February Journal of Vascular Surgery stating that disparities in limb salvage procedures may be driven by socioeconomic status and access to high-volume hospitals.

29 Jan 2011

BioTime announces acquisition of CTI assets

BioTime, today announced that it has acquired substantially all the assets of Cell Targeting, a Cleveland, Ohio-based biotechnology company conducting research in regenerative medicine.

29 Jan 2011